{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T18:44:28Z","timestamp":1768675468755,"version":"3.49.0"},"reference-count":45,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"48","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1097\/md.0000000000008813","type":"journal-article","created":{"date-parts":[[2017,11,28]],"date-time":"2017-11-28T22:05:35Z","timestamp":1511906735000},"page":"e8813","source":"Crossref","is-referenced-by-count":6,"title":["Achieving stable remission with maintenance electroconvulsive therapy in a patient with treatment-resistant schizophrenia"],"prefix":"10.1097","volume":"96","author":[{"given":"Sebastian","family":"Moeller","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neele","family":"Kalkwarf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"L\u00fccke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Jahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christiane","family":"F\u00f6rst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niclas","family":"Braun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Philipsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helge H.O.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-40-20210226","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1517\/14656566.2011.528200","article-title":"Pharmacotherapy for treatment-refractory schizophrenia","volume":"12","author":"Van Sant","year":"2011","journal-title":"Expert Opin Pharmacother"},{"key":"R2-40-20210226","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1093\/schbul\/23.4.663","article-title":"Evaluation of treatment-resistant schizophrenia","volume":"23","author":"Conley","year":"1997","journal-title":"Schizophr Bull"},{"key":"R3-40-20210226","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12888-016-1177-y","article-title":"Is treatment-resistant schizophrenia categorically distinct from treatment-responsive schizophrenia? A systematic review","volume":"17","author":"Gillespie","year":"2017","journal-title":"BMC Psychiatry"},{"key":"R4-40-20210226","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.psychres.2012.02.013","article-title":"Defining treatment-resistant schizophrenia and response to antipsychotics: a review and recommendation","volume":"197","author":"Suzuki","year":"2012","journal-title":"Psychiatry Res"},{"key":"R5-40-20210226","doi-asserted-by":"crossref","first-page":"e0156510","DOI":"10.1371\/journal.pone.0156510","article-title":"Electroconvulsive therapy added to non-clozapine antipsychotic medication for treatment resistant schizophrenia: meta-analysis of randomized controlled trials","volume":"11","author":"Zheng","year":"2016","journal-title":"PLoS One"},{"key":"R6-40-20210226","first-page":"125","article-title":"Concept and management of treatment resistant schizophrenia (TRS)","volume":"46","author":"Painuly","year":"2004","journal-title":"Indian J Psychiatry"},{"key":"R7-40-20210226","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0010-440X(90)90038-T","article-title":"A review of clozapine: an antipsychotic for treatment-resistant schizophrenia","volume":"31","author":"Stephens","year":"1990","journal-title":"Compr Psychiatry"},{"key":"R8-40-20210226","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1186\/1471-244X-14-102","article-title":"Clozapine: a review of clinical practice guidelines and prescribing trends","volume":"14","author":"Warnez","year":"2014","journal-title":"BMC Psychiatry"},{"key":"R9-40-20210226","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/schbul\/sbx008","article-title":"A systematic and meta-analytic review of neural correlates of functional outcome in schizophrenia","volume":"21","author":"Wojtalik","year":"2017","journal-title":"Schizophr Bull"},{"key":"R10-40-20210226","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.psychres.2017.01.064","article-title":"The critical treatment window of clozapine in treatment-resistant schizophrenia: secondary analysis of an observational study","volume":"250","author":"Yoshimura","year":"2017","journal-title":"Psychiatry Res"},{"key":"R11-40-20210226","doi-asserted-by":"crossref","first-page":"e498","DOI":"10.4088\/JCP.16r10782","article-title":"Clozapine augmentation with antiepileptic drugs for treatment-resistant schizophrenia: a meta-analysis of randomized controlled trials","volume":"78","author":"Zheng","year":"2017","journal-title":"J Clin Psychiatry"},{"key":"R12-40-20210226","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0140-6736(95)91630-X","article-title":"Treatment of schizophrenia","volume":"346","author":"Kane","year":"1995","journal-title":"Lancet"},{"key":"R13-40-20210226","first-page":"65","article-title":"Dosing issues and depot medication in the maintenance treatment of schizophrenia","volume":"10","author":"Kane","year":"1995","journal-title":"Int Clin Psychopharmacol"},{"key":"R14-40-20210226","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1192\/bjp.162.1.38","article-title":"Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom","volume":"162","author":"Davies","year":"1993","journal-title":"Br J Psychiatry"},{"key":"R15-40-20210226","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1192\/bjp.180.4.351","article-title":"Psychosis in high-security and general psychiatric services: report from the UK700 and special hospitals\u2019 treatment resistant schizophrenia groups","volume":"180","author":"Walsh","year":"2002","journal-title":"Br J Psychiatry"},{"key":"R16-40-20210226","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3109\/13651509909022729","article-title":"Pharmacological treatment of schizophrenia resistant to first-line treatment: a critical systematic review and meta-analysis","volume":"3","author":"Cheine","year":"1999","journal-title":"Int J Psychiatry Clin Pract"},{"key":"R17-40-20210226","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.schres.2016.09.016","article-title":"Response to antipsychotic drugs in treatment-resistant schizophrenia: conclusions based on systematic review","volume":"178","author":"Molins","year":"2016","journal-title":"Schizophr Res"},{"key":"R18-40-20210226","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/YIC.0b013e32836508e6","article-title":"The social and economic burden of treatment-resistant schizophrenia: a systematic literature review","volume":"29","author":"Kennedy","year":"2014","journal-title":"Int Clin Psychopharmacol"},{"key":"R19-40-20210226","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1017\/S1092852912000806","article-title":"Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses","volume":"18","author":"Souza","year":"2013","journal-title":"CNS Spectr"},{"key":"R20-40-20210226","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.schres.2011.09.016","article-title":"Treatment resistant schizophrenia and response to antipsychotics: a review","volume":"133","author":"Suzuki","year":"2011","journal-title":"Schizophr Res"},{"key":"R21-40-20210226","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.schres.2014.02.015","article-title":"A six month randomized controlled trial of long acting injectable risperidone 50 and 100\u200amg in treatment resistant schizophrenia","volume":"154","author":"Meltzer","year":"2014","journal-title":"Schizophr Res"},{"key":"R22-40-20210226","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.pnpbp.2015.08.010","article-title":"Treatment resistant schizophrenia is associated with the worst community functioning among severely-ill highly-disabling psychiatric conditions and is the most relevant predictor of poorer achievements in functional milestones","volume":"65","author":"Iasevoli","year":"2016","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R23-40-20210226","first-page":"51","article-title":"Clinical predictors of response to clozapine in patients with treatment resistant schizophrenia","volume":"44","author":"Rajkumar","year":"2011","journal-title":"Psychopharmacol Bull"},{"key":"R24-40-20210226","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1192\/bjp.210.4.299","article-title":"Clozapine in treatment-resistant schizophrenia","volume":"210","author":"Samara","year":"2017","journal-title":"Br J Psychiatry"},{"key":"R25-40-20210226","first-page":"CD006324","article-title":"Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia","volume":"3","author":"Barber","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R26-40-20210226","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/s40263-017-0411-6","article-title":"Clozapine for treatment-resistant schizophrenia: still the gold standard?","volume":"31","author":"Taylor","year":"2017","journal-title":"CNS Drugs"},{"key":"R27-40-20210226","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.schres.2016.01.024","article-title":"Augmentation of clozapine with electroconvulsive therapy in treatment resistant schizophrenia: a systematic review and meta-analysis","volume":"171","author":"Lally","year":"2016","journal-title":"Schizophr Res"},{"key":"R28-40-20210226","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1080\/14740338.2016.1191468","article-title":"Clozapine's critical role in treatment resistant schizophrenia: ensuring both safety and use","volume":"15","author":"Remington","year":"2016","journal-title":"Expert Opin Drug Saf"},{"key":"R29-40-20210226","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/acps.12290","article-title":"Every patient with treatment resistant schizophrenia should know the meaning of the term \u2019clozapine\u2019","volume":"130","author":"Nielsen","year":"2014","journal-title":"Acta Psychiatr Scand"},{"key":"R30-40-20210226","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3109\/10398562.2011.602078","article-title":"Clozapine use and outcomes among patients with treatment resistant schizophrenia","volume":"19","author":"El-Badri","year":"2011","journal-title":"Australas Psychiatry"},{"key":"R31-40-20210226","first-page":"7093","article-title":"Electroconvulsive therapy hasn\u2019t negative effects on short-term memory function, as assessed using a bedside hand-held device","volume":"9","author":"M\u00fcller","year":"2017","journal-title":"Ment Illn"},{"key":"R32-40-20210226","first-page":"309","article-title":"The mode of action of ECT","volume":"30","author":"Fink","year":"1994","journal-title":"Psychopharmacol Bull"},{"key":"R33-40-20210226","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/00124509-199812000-00012","article-title":"Concurrent administration of clozapine and ECT: a successful therapeutic strategy for a patient with treatment-resistant schizophrenia","volume":"14","author":"Bhatia","year":"1998","journal-title":"J ECT"},{"key":"R34-40-20210226","doi-asserted-by":"crossref","first-page":"245","DOI":"10.4103\/0019-5545.43067","article-title":"Combination of ECT and clozapine in drug-resistant schizophrenia","volume":"47","author":"Kurian","year":"2005","journal-title":"Indian J Psychiatry"},{"key":"R35-40-20210226","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00124509-199812000-00001","article-title":"ECT and clozapine in schizophrenia","volume":"14","author":"Fink","year":"1998","journal-title":"J ECT"},{"key":"R36-40-20210226","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/S0924-9338(98)80008-4","article-title":"ECT followed by clozapine treatment in acute situations of schizophrenia","volume":"13","author":"Castelnau","year":"1998","journal-title":"Eur Psychiatry"},{"key":"R37-40-20210226","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s12888-014-0253-4","article-title":"Treatment resistant schizophrenia: a comprehensive survey of randomised controlled trials","volume":"14","author":"Sinclair","year":"2014","journal-title":"BMC Psychiatry"},{"key":"R38-40-20210226","first-page":"446","article-title":"Treatment resistant schizophrenia: therapeutic approaches [in Spanish]","volume":"16","author":"Leiderman","year":"2005","journal-title":"Vertex"},{"key":"R39-40-20210226","first-page":"48","article-title":"Pharmacological treatment resistant schizophrenia [in Spanish]","volume":"34","author":"Cervera Enguix","year":"2006","journal-title":"Actas Esp Psiquiatr"},{"key":"R40-40-20210226","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1111\/j.1440-1819.2005.01402.x","article-title":"Continuation electroconvulsive therapy for relapse prevention in middle-aged and elderly patients with intractable catatonic schizophrenia","volume":"59","author":"Suzuki","year":"2005","journal-title":"Psychiatry Clin Neurosci"},{"key":"R42-40-20210226","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YCT.0b013e31815ef238","article-title":"Strategies to minimize cognitive side effects with ECT: aspects of ECT technique","volume":"24","author":"Prudic","year":"2008","journal-title":"J ECT"},{"key":"R43-40-20210226","first-page":"853","article-title":"Patients with schizophrenia or schizoaffective disorder who receive multiple electroconvulsive therapy sessions: characteristics, indications, and results","volume":"11","author":"Iancu","year":"2015","journal-title":"Neuropsychiatr Dis Treat"},{"key":"R44-40-20210226","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.3389\/fpsyg.2016.01642","article-title":"The proximity between hallucination and delusion dimensions: an observational, analytic, cross-sectional, multicentre study","volume":"7","author":"Telles-Correia","year":"2016","journal-title":"Front Psychol"},{"key":"R45-40-20210226","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.schres.2015.05.021","article-title":"The relationship between Positive and Negative Syndrome Scale (PANSS) schizophrenia severity scores and risk for hospitalization: an analysis of the CATIE Schizophrenia Trial","volume":"166","author":"Glick","year":"2015","journal-title":"Schizophr Res"},{"key":"R46-40-20210226","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12888-015-0554-2","article-title":"Symptom profile and short term outcome of catatonia: an exploratory clinical study","volume":"15","author":"Worku","year":"2015","journal-title":"BMC Psychiatry"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000008813","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T02:43:24Z","timestamp":1620960204000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201712010-00040"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2017,12]]},"references-count":45,"journal-issue":{"issue":"48","published-print":{"date-parts":[[2017]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000008813","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2017,12]]}}}